Stress-Activated Cytokines and The Heart: From Adaptation to Maladaptation

Annual Review of Physiology

Volumn 65, Issue , 2003, Pages 81-101

  Mann, Douglas L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Contractility; Homeostasis; IL 1; IL 6; Stress; TNF

Indexed keywords

CYTOKINE;

ADAPTATION; APOPTOSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR SYSTEM; CELL LOSS; CELL PROTECTION; EXPERIMENTAL MOUSE; GENE EXPRESSION; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE CONTRACTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTROPHY; MALADJUSTMENT; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PHYLOGENY; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; STRESS; ANIMAL; HEART; IMMUNOLOGY; PHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CYTOKINES; HEART; HUMANS; MYOCARDIUM; STRESS;

EID: 0013065280     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.65.092101.142249     Document Type: Review

References (102)

1. Hammond GL, Wieben E, Markert CL. 1979. Molecular signals for initiating protein synthesis in organ hypertrophy. Proc. Natl. Acad. Sci. USA 76:2455-55
2. Hammond GL, Lai YK, Markert CL. 1982. The molecules that initiate cardiac hypertrophy are not species specific. Science 216:529-31
3. Hammond GL, Lai YK, Markert CL. 1984. Preliminary characterization of molecules that increase cell free translational activity of cardiac cytoplasmic RNA. Eur. Heart J. 5(Suppl. F):225-29
4. Casscells W, Speir E, Sasse J, Klagsbrun M, Allen P, et al. 1990. Isolation, characterization, and localization of heparin-binding growth factors in the heart. J. Clin. Invest. 85:433-41
5. 1 in the normal rat myocardium. Tissue Res. 256:553-58
6. Weiner HL, Swain JL. 1989. Acidic fibroblast growth factor mRNA is expressed by cardiac myocytes in culture and the protein is localized to the extracellular matrix. Proc. Natl. Acad. Sci. USA 86:2683-87
7. Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM. 1993. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ. Res. 72:1245-54
8. Sadoshima JI, Xu Y, Slayter HS, Izumo S. 1993. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75:977-84
9. Li J, Hampton T, Morgan JP, Simons M. 1997. Stretch-induced VEGF expression in the heart. J. Clin. Invest. 100:18-24
10. Yue P, Long CS, Austin R, Chang KC, Simpson PC, Massie BM. 1998. Post-infarction heart failure in the rat is associated with distinct alterations in cardiac myocyte molecular phenotype. J. Mol. Cell. Cardiol. 30:1615-30
11. Goto M, Liu Y, Yang XM, Ardell JL, Cohen MV, Downey JM. 1995. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ. Res. 77:611-21
12. Downey JM, Liu GS, Thornton JD. 1993. Adenosine and the anti-infarct effects of preconditioning. Cardiovasc. Res. 27:3-8
13. Bolli R, Bhatti ZA, Tang XL, Qiu Y, Zhang Q, et al. 1997. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. Circ. Res. 81:42-52
14. Kapadia S, Lee JR, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. 1995. Tumor necrosis factor gene and protein expression in adult feline myocardium after endotoxin administration. J. Clin. Invest. 96:1042-52
15. Kapadia S, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. 1997. Hemodynamic regulation of tumor necrosis factor-α gene and protein expression in adult feline myocardium. Circ. Res. 81:187-95
16. Hoffmann JA, Kafatos FC, Janeway CA Jr, Ezekowitz RA. 1999. Phylogenetic perspectives in innate immunity. Science 284:1313-18
17. Raftos DA, Cooper EL, Habicht GS, Beck G. 1991. Invertebrate cytokines: tunicate cell proliferation stimulated by an interleukin 1-like molecule. Proc. Natl. Acad. Sci. USA 88:9518-22
18. Beck G, Habicht GS. 1991. Primitive cytokines: harbingers of vertebrate defense. Immunol. Today 12:180-83
19. Eddy LJ, Goeddel DV, Wong GHW. 1992. Tumor necrosis factor-α pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem. Biophys. Res. Commun. 184:1056-59
20. Nelson SK, Wong GHW, McCord JM. 1995. Leukemia inhibitory factor and tumor necrosis factor induce manganese superoxide dismutase and protect rabbit hearts from reperfusion injury. J. Mol. Cell. Cardiol. 27:223-29
21. Terracio L, Miller B, Borg TK. 1988. Effects of cyclic mechanical stimulation of the cellular components of the heart: in vitro. Cell. Dev. Biol. 24:53-58
22. Maulik N, Engelman RM, Wei ZJ, Lu D, Rousou JA, Das DK. 1993. Interleukin-1 alpha preconditioning reduces myocardial ischemia reperfusion injury. Circulation 88:387-94
23. Nakano M, Knowlton AA, Dibbs Z, Mann DL. 1998. Tumor necrosis factor-α confers resistance to injury induced by hypoxic injury in the adult mammalian cardiac myocyte. Circulation 97:1392-400
24. Wong GHW, Goeddel DV. 1988. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242:941-44
25. Nakano M, Knowlton AA, Yokoyama T, Lesslauer W, Mann DL. 1996. Tumor necrosis factor-α induced expression of heat shock protein 72 in adult feline cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 270:H1231-H39
26. Low-Friedrich I, Weisensee D, Mitrou P, Schoeppe W. 1992. Cytokines induce stress protein formation in cultured cardiac myocytes. Basic Res. Cardiol. 87:12-1
27. Marber MS, Mestril R, Chi SH, Sayen R, Yellon DM, Dillmann WH. 1995. Overexpression of the rat inducible 70-kd heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J. Clin. Invest. 95:1446-56
28. Plumier JCL, Ross BM, Currie RW, Angelides CE, Kazlaris H, et al. 1995. Transgenic mice expressing the human heat shock protein 70 have improved post-ischemic myocardial recovery. J. Clin. Invest. 95:1854-60
29. Narula J, Pandey P, Arbustini E, Haider N, Narula N, et al. 1999. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc. Natl. Acad. Sci. USA 96:8144-49
30. Erl W, Hansson GK, de Martin R, Draude G, Weber KS, Weber C. 1999. Nuclear factor-kappa B regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ. Res. 84:668-77
31. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin ASJ. 1998. NF-kappa B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 281:1680-83
32. Stehlik C, de Martin R, Binder BR, Lipp J. 1998. Cytokine induced expression of porcine inhibitor of apoptosis protein (iap) family member is regulated by NF-kappa B. Biochem. Biophys. Res. Commun. 243:827-32
33. Lee JP, Palfrey HC, Bindokas VP, Ghadge GD, Ma L, et al. 1999. The role of immunophilins in mutant superoxide dismutase-1linked familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 96:3251-56
34. Fujio Y, Kunisada K, Hirota H, Yamauchi-Takihara K, Kishimoto T. 1997. Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J. Clin. Invest. 99:2898-905
35. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, et al. 1996. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. USA 93:407-11
36. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, et al. 1999. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97:189-98
37. Kurrelmeyer K, Michael L, Baumgarten G, Taffet G, Peschon J, et al. 2000. Endogenous myocardial tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc. Natl. Acad. Sci. USA 290:5456-61
38. Rothe M, Sarma V, Dixit VM, Goeddel DV. 1995. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40. Science 269:1424-27
39. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman ML, Mann DL. 1997. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 95:1247-52
40. Bozkurt B, Kribbs S, Clubb FJ Jr, Michael LH, Didenko W, et al. 1998. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97:1382-91
41. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, et al. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234:470-74
42. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, et al. 1989. The cardiovascular response of normal humans to the administration of endotoxin. N. Engl. J. Med. 321:280-87
43. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, et al. 1988. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J. Natl. Cancer Inst. 80:1039-44
44. Blick M, Sherwin SA, Rosenblum M, Gutterman J. 1987. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 47:2986-89
45. Selby P, Hobbs S, Viner C, Jackson E, Jones A, et al. 1987. Tumor necrosis factor in man: clinical and biological observations. Brit. J. Cancer 56:803-8
46. Gulick TS, Chung MK, Pieper SJ, Lange LG, Schreiner GF. 1989. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc. Natl. Acad. Sci. USA 86:6753-57
47. Chung MK, Gulick TS, Rotondo RE, Schreiner GF, Lange LG. 1990. Mechanism of action of cytokine inhibition of β-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes: impairment of signal transduction. Circ. Res. 67:753-63
48. Gulick TS, Pieper JS, Murphy MA, Lange LG, Schreiner GF. 1991. A new method for assessment of cultured cardiac myocyte contractility detects immune factor-mediated inhibition of β-adrenergic responses. Circulation 84:313-21
49. Balligand JL, Ungureanu D, Kelly RA, Kobzik L, Pimental D, et al. 1993. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J. Clin. Invest. 91:2314-19
50. Natanson C, Eichenholz PW, Danner RL, Eichacker W, Hoffman D, et al. 1989. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J. Exp. Med. 169:823-32
51. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. 1992. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J. Clin. Invest. 90:389-98
52. Eichenholz PW, Eichacker PQ, Hoffman WD, Banks SM, Parrillo JE, et al. 1992. Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 263:H668-H75
53. Murray DR, Freeman GL. 1996. Tumor necrosis factor-α induces a biphasic effect on myocardial contractility in conscious dogs. Circ. Res. 78:154-60
54. Hosenpud JD. 1993. The effects of interleukin-1 on myocardial function and metabolism. Clin. Immunol. Immunopathol. 68:175-80
55. Schulz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuk GD. 1995. The role of nitric oxide in cardiac depression induced by interleukin-1β and tumour necrosis factor-α. Br. J. Pharmacol. 114:27-34
56. Roberts AB, Roche NS, Winokur TS, Burmester JK, Sporn MB. 1992. Role of transforming growth factor-β in maintenance of function of cultured neonatal cardiac myocytes: autocrine action and reversal of damaging effects of interleukin-1. J. Clin. Invest. 90:2056-62
57. Roberts AB, Vodovotz Y, Roche NS, Sporn MB, Nathan CF. 1992. Role of nitric oxide in antagonistic effects of transforming growth factor-β and interleukin-1β on the beating rate of cultured myocytes. Mol. Endocrinol. 6:1921-30
58. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. 1992. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257:387-89
59. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. 1993. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J. Clin. Invest. 92:2303-12
60. i and cell contraction in cultured chick ventricular myocytes. Circ. Res. 75:285-95
61. Mann DL. 1996. Stress activated cytokines and the heart. Cytokine Growth Factor Rev. 7:341-54
62. Meldrum DR. 1998. Tumor necrosis factor in the heart. Am. J. Physiol. Regulatory Integrative Comp. Physiol. 274:R577-R95
63. Cohn JN. 1995. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 91:2504-7
64. Kubota T, McTiernan CF, Frye CS, Slawson SE, Koretsky AP, et al. 1997. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-alpha. Circ. Res. 81:627-35
65. Thaik CM, Calderone A, Takahashi N, Colucci WS. 1995. Interleukin-1β modulates the growth and phenotype of neonatal rat cardiac myocytes. J. Clin. Invest. 96:1093-99
66. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, et al. 1996. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J. Clin. Invest. 98:2854-65
67. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, et al. 2000. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc. Natl. Acad. Sci. USA 97:12746-51
68. Sivasubramanian N, Coker ML, Kurrelmeyer K, DeMayo F, Spinale FG, Mann DL. 2001. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001:826-31
69. Weber KT. 1989. Cardiac intersitium in health and disease: the fibrillar collagen network. J. Am. Coll. Cardiol. 13(7):1637-52
70. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, Ramadori G. 2000. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem. Cell Biol. 113:443-53
71. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, et al. 1998. Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am. J. Pathol. 153:825-32
72. Smith SC, Allen PM. 1992. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. Circ. Res. 70:856-63
73. Matsumori A, Yamada T, Kawai C. 1991. Immunomodulating therapy in viral myocarditis: effects of tumour necrosis factor, interleukin 2 and anti-interleukin-2 receptor antibody in an animal model. Eur. Heart J. 12:203-5
74. Arbustini E, Grasso M, Diegoli M, Bramerio M, Foglieni AS, et al. 1991. Expression of tumor necrosis factor in human acute cardiac rejection: an immunohistochemical and immunoblotting study. Am. J. Pathol. 139:709-15
75. Sakobar A, Horton JD, Bowler K, Manning R, Meager A, Dark JH. 1993. Raised levels of tumor-necrosis factor alpha (TNFα) in cardiac transplant patients. Clin. Transplantation 7:459-66
76. Maury CPJ, Teppo AM. 1989. Circulating tumour necrosis factor-α (cachectin) in myocardial infarction. J. Intern. Med. 225:333-36
77. Basaran Y, Basaran MM, Babacan KF, Ener B, Okay T, et al. 1993. Serum tumor necrosis factor levels in acute myocardial infarction and unstable angina pectoris. Angiology 44:332-37
78. Ikeda U, Ohkawa F, Seino Y, Yamamoto K, Hidaka Y, et al. 1992. Serum interleukin 6 levels become elevated in acute myocardial infarction. J. Mol. Cell. Cardiol. 24:579-84
79. Miyao Y, Yasue H, Ogawa H, Misumi I, Masuda T, et al. 1993. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am. Heart J. 126:1299-304
80. Cruickshank AM, Oldroyd KG, Cobbe SM. 1994. Serum interleukin-6 in suspected myocardial infarction. Lancet 343:974
81. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. 1994. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br. Heart J. 72:561-66
82. Lefer AM, Tsao P, Aoki N, Palladino MA Jr. 1990. Mediation of cardioprotection by transforming growth factor-β. Science 249:61-64
83. Herskowitz A, Choi S, Ansari AA, Wesselingh S. 1995. Cytokine mRNA expression in postischemic/reperfused myocardium. Am. J. Pathol. 146:419-28
84. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. 1990. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 223:236-41
85. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. 1993. Tumour necrosis factor-alpha in severe congestive cardiac failure. Br. Heart J. 70:141-43
86. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. 1996. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 347:1151-55
87. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, et al. 1996. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 93:704-11
88. Torre-Amione G, Kapadia S, Benedict CR, Oral H, Young JB, Mann DL. 1996. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J. Am. Coll. Cardiol. 27:1201-6
89. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, et al. 1995. Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure. Circulation 92:1479-86
90. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, et al. 1994. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in the forearm. Circulation 90:12-16
91. McMurray J, Abdullah I, Dargie HJ, Shapiro D. 1991. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br. Heart J. 66:356-58
92. Jansen NJG, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CRH. 1992. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann. Thorac. Surg. 54:744-48
93. Lahat N, Zlotnick AY, Shtiller R, Bar I, Merin G. 1992. Serum levels of IL-1, IL-6 and tumor necrosis factors in patients undergoing coronary artery bypass grafts or cholecystectomy. Clin. Exp. Immunol. 89:255-60
94. Butler J, Pillai R, Rocker GM, Westaby S, Parker D, Shale DJ. 1993. Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor. J. Thorac. Cardiovasc. Surg. 105:25-30
95. Wan S, Marchant A, Desmet JM, Antoine M, Zhang HB, et al. 1996. Human cytokine responses to cardiac transplantation and coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 111:469-77
96. Weglicki WB, Phillips TM. 1992. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am. J. Physiol. Regulatory Integrative Comp. Physiol. 263:R734-R37
97. Weglicki WB, Phillips TM, Freedman AM, Cassidy MM, Dickens BF. 1992. Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol. Cell. Biochem. 110:169-73
98. Millar AB, Singer M, Meager A, Foley NM, Johnson NM, Rook GA. 1989. Tumor necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet 2:712-13
99. Hegewisch S, Weh HJ, Hossfeld DK. 1990. TNF-induced cardiomyopathy. Lancet 2:294-95
100. Semb H, Peterson J, Tavernier J, Olivecrona T. 1987. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J. Biol. Chem. 262:8390-94
101. Lancaster JR Jr, Laster SM, Gooding LR. 1989. Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor. FEBS Lett. 248:169-74
102. Stadler J, Bentz BG, Harbrecht BG, Disilvio M, Curran RD, et al. 1992. Tumor necrosis factor alpha inhibits hepatocyte mitochondrial respiration. Ann. Surg. 216:539-46